Skip to main content
    A

    Armata Pharmaceuticals Inc (ARMP)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • AMEX

    $2.63
    -0.36 (-12.04%)

    Market Cap: $111.21M

    Last updated: Nov 17, 2026 at 4:16 PM ET

    Armata Pharmaceuticals Inc (ARMP) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Armata Pharmaceuticals (ARMP) has a market cap of $111.21M and an enterprise value of $314.36M. It kept -1464.54% of revenue as net income over the last 12 months. Revenue grew 49.49% over the last 12 months from the 12 months before.

    Total Valuation

    Enterprise value is 182.68% above the market cap, as debt exceeds cash.

    Market Cap$111.21M
    Enterprise Value$314.36M
    Latest price (Nov 17, 2026)$2.63

    Key Dates

    The next earnings report is expected on Mar 17, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 17, 2027 (expected)
    Last Earnings DateNov 12, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 1.18% in the quarter ended Sep 30, 2026 and grew 1.37% a year over 2 years.

    Shares Outstanding37.18M
    Shares Change (YoY)+2.64%
    Shares Change (QoQ)+1.18%
    Share Count Growth (2Y CAGR)+1.37%

    Valuation Ratios

    The price to sales ratio is 12.9x. Its year-end P/S ranged from 7.7x to 66.8x from 2016 to 2025.

    P/S Ratio12.9x
    Forward P/S33.7x

    Price Statistics

    The stock is down 64.07% over 52 weeks and trades 28.53% below its 50-day average.

    Beta (1Y)1.03
    52-Week Change-64.07%
    1-Month Change-14.33%
    3-Month Change-48.13%
    6-Month Change-68.91%
    5-Year Change+2.50%
    10-Year Change-98.02%
    Total Return (1Y)-64.07%
    Total Return (3Y CAGR)+5.81%
    Total Return (5Y CAGR)-7.63%
    Return vs SPY (1Y)-73.33%
    Max Drawdown (1Y)-82.23%
    Max Drawdown (3Y)-82.23%
    Sharpe Ratio (1Y)-0.84
    Correlation with SPY (1Y)0.12
    50-Day Average$3.68
    200-Day Average$6.83
    52-Week Range$2.75 to $14.98
    RSI (14 Days)37.5
    Average Volume (20 Days)87.68K

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 0.12x current liabilities.

    Current Ratio0.12x
    Quick Ratio0.12x

    Returns and Efficiency

    Return on invested capital is -184.64% over the last 12 months.

    Return on Assets (ROA)-130.98%
    Return on Invested Capital (ROIC)-184.64%
    ROA (5Y Average)-77.97%
    Asset Turnover0.09x

    Scores

    ARMP has an Altman Z-Score of -14.42, in the distress zone below 1.81, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.

    Altman Z-Score-14.42
    Altman Z ZoneDistress
    Piotroski F-Score3 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue was $7.55M over the last 12 months.

    Revenue$7.55M
    Revenue Growth (YoY)+49.49%
    Gross Profit$7.55M
    Operating Income-$40.30M
    Pretax Income-$110.65M
    Net Income-$110.65M
    EBIT-$110.65M
    Reported EPS (TTM)-$4.18

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Cash and Equivalents$18.32M
    Total Debt$221.47M
    Net Debt$203.15M
    Net Debt Per Share$5.46
    Working Capital-$164.18M
    Shareholder Equity-$174.13M
    Tangible Book Value-$187.87M
    Total Assets$84.48M
    Total Liabilities$258.61M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $223.00K of capital spending, operating cash flow left -$26.86M of free cash flow.

    Operating Cash Flow-$26.64M
    Capital Expenditures$223.00K
    Free Cash Flow-$26.86M
    FCF Per Share-$0.72
    Depreciation and Amortization$2.04M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -533.46%.

    Gross Margin100.00%
    Operating Margin-533.46%
    Pretax Margin-1464.54%
    Net Margin-1464.54%
    EBIT Margin-1464.54%
    FCF Margin-355.54%

    Growth

    Revenue fell 3.80% a year over 3 years.

    Revenue Growth (3Y CAGR)-3.80%
    Revenue Growth (5Y CAGR)+42.90%

    Revenue and profit by year

    Dividends and Yields

    ARMP does not pay a dividend. Its free cash flow yield is -27.47%.

    FCF Yield-27.47%
    Shareholder Yield0.00%

    Stock Splits

    The last split was a 1-for-14 reverse split on May 10, 2019.

    Last Split DateMay 10, 2019
    Split TypeReverse split
    Split Ratio1:14

    Peer Position

    Against 8 similar companies, ARMP has the 4th highest P/S.

    P/S Ratio12.9x vs 5.1x median
    ROIC-184.64% vs -51.32% median
    Revenue Growth (Trailing 4 Quarters, YoY)+49.49% vs +2.54% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at -25.12% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)-25.12%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About ARMP

    What is ARMP's market cap?

    Armata Pharmaceuticals has a market cap of $111.21M. Its enterprise value, which adds debt and subtracts cash, is $314.36M.

    How many shares of ARMP are outstanding?

    Armata Pharmaceuticals has 37.18M shares outstanding. The count is up 2.64% from a year earlier.

    Does ARMP pay a dividend?

    No. Armata Pharmaceuticals does not pay a dividend.

    How much debt does ARMP have?

    Armata Pharmaceuticals has $221.47M of total debt and $18.32M of cash and equivalents, a net debt position of $203.15M.